COR Cencora (COR) Insider Trading, Ownership & Congress Trades
Wholesale & Retail · Wholesale-drugs, proprietaries & druggists' sundries · CIK 0001140859
Congress · 1Form 144 · 6
Funds added, last quarter
550
13F, latest reported quarter
What the filings say about COR
Insiders, 180 days
-$2.4M net sold
2 buyers · 3 sellers · 50% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2026-05-06
Planned sales (Form 144), 90 days
$16.4M
6 notices
Cencora insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Cencora, Inc. insiders sold a net $2.4M of stock across 108 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Sep 1, 2026.
- The trade is 6.5% of the 15,183 shares held after it.
- 1 other insider sold within 30 days.
- 550 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & Chief Accounting Officer Krikorian Lazarus sold about $298.9K of COR under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 550 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 14, 2025.
- The trade is 7.5% of the 17,128 shares held after it.
- 2 other insiders sold within 30 days.
- 550 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director GREENBERG LON R sold about $411.3K of COR on Sep 16, 2026; 2 other insiders sold within 30 days and 550 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Dec 17, 2025.
- The trade is 6.1% of the 16,169 shares held after it.
- 2 other insiders sold within 30 days.
- 550 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & Chief Accounting Officer Krikorian Lazarus sold about $321.1K of COR under a 10b5-1 plan on Sep 1, 2026; 2 other insiders sold within 30 days and 550 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Dec 19, 2025.
- The trade is 58.1% of the 19,455 shares held after it.
- 2 other insiders sold within 30 days.
- 550 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice President Campbell Elizabeth S sold about $3.7M of COR on Aug 24, 2026; 2 other insiders sold within 30 days and 550 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 12.6% of the 4,359 shares held after it.
- 1 other insider bought within 30 days.
- 550 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Tyler Lauren M bought about $148.6K of COR on Jun 22, 2026; 1 other insider bought within 30 days and 550 funds added in the latest 13F quarter.108 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.4M over 180 days
-$4.7M over 90 days
below 58% of Wholesale & Retail
Congress
1 member bought in the last year
the lowest in Wholesale & Retail
Funds
550 funds bought in last quarter
more than 92% of Wholesale & Retail
Revenue
+9.3% year over year
more than 72% of Wholesale & Retail
Margin
0.5% net margin
below 59% of Wholesale & Retail
Buybacks
$435.5M repurchased, FY to 2025-09-30
more than 85% of Wholesale & Retail
Short interest
2.2% of the float short (float per yahoo 2026-10-26) · 2.9 days to cover · settled 2026-09-30
below 57% of Wholesale & Retail
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.
Oct 5SVP & Chief Accounting Officer Krikorian Lazarus sold $298.9K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Watch COR
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+1.2%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns COR: institutional holders (13F)
13F holdings, latest reported quarter
18,213,783 sh
$5.2B
12,378,943 sh
$3.5B
9,611,756 sh
$2.7B
9,273,983 sh
$2.6B
5,943,657 sh
$1.7B
Congress trades in COR
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-05-06 · disclosed 44 days later
$1,001 - $15,000
Bought 2026-03-31 · disclosed 30 days later
$1,001 - $15,000
Bought 2026-03-23 · disclosed 38 days later
$1,001 - $15,000
Sold 2025-05-12 · disclosed 41 days later
$50,001 - $100,000
Sold 2025-03-27 · disclosed 12 days later
$15,001 - $50,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
COR planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Lon Greenberg
Filed 2026-09-16
$411.3K
Battaglia Silvana
Filed 2026-09-11
$430.3K
Cleary James F
Filed 2026-09-04
$3.4M
Battaglia Silvana
Filed 2026-09-01
$2.2M
Campbell Elizabeth S
Filed 2026-08-24
$3.7M
COR mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Health Care Services Portfolio
$37.4M position · as of 2026-05-31
4.6%
LIVE OAK HEALTH SCIENCES FUND
$2.5M position · as of 2026-07-31
4.5%
Saratoga Health & Biotechnology Fund
$453.3K position · as of 2026-05-31
4.3%
AdvisorShares Focused Equity ETF
$4.5M position · as of 2026-06-30
3.4%
VanEck Pharmaceutical ETF
$29.5M position · as of 2026-06-30
3.4%
Goldman Sachs Variable Insurance Trust Mid Cap Growth Fund
$2.5M position · as of 2026-06-30
3.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Cencora, Inc. Pac
Cycle 2026 · $986K spent
$714.5K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Robert P. Mauch
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$18.3M
$33.9M
$6.1M
+242%
+44%
2024
$18.5M
$61.4M
$7.8M
+144%
+56%
2023
$17.5M
$33.8M
$5.1M
+93%
+28%
2022
$16.7M
$26.1M
$4.4M
+44%
+18%
2021
$14.9M
$39.8M
$4.6M
+25%
+23%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.4M sold by insiders over 180 days, 550 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $16.4M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
COR financials
Revenue growth
+9.3%
XBRL, annual
Net margin
0.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$332.8B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM COR
| FY Sep 2025 | $321.3B |
| FY Sep 2024 | $294.0B |
| FY Sep 2023 | $262.2B |
| FY Sep 2022 | $238.6B |
| FY Sep 2021 | $214.0B |
| Jun 2026 | $84.8B |
| Mar 2026 | $78.4B |
| Dec 2025 | $85.9B |
| Sep 2025 | $83.7B |
| Jun 2025 | $80.7B |
| Mar 2025 | $75.5B |
| Dec 2024 | $81.5B |
| Sep 2024 | $79.1B |
At each fiscal year end
Single quarter
Net margin, TTM
+0.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM COR
| FY Sep 2025 | +0.5% |
| FY Sep 2024 | +0.5% |
| FY Sep 2023 | +0.7% |
| FY Sep 2022 | +0.7% |
| FY Sep 2021 | +0.7% |
| Jun 2026 | +0.9% |
| Mar 2026 | +2.1% |
| Dec 2025 | +0.7% |
| Sep 2025 | -0.4% |
| Jun 2025 | +0.9% |
| Mar 2025 | +1.0% |
| Dec 2024 | +0.6% |
| Sep 2024 | +0.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$4.1B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM COR
| FY Sep 2025 | $3.2B |
| FY Sep 2024 | $3.0B |
| FY Sep 2023 | $3.5B |
| FY Sep 2022 | $2.2B |
| FY Sep 2021 | $2.2B |
| Jun 2026 | $2.4B |
| Mar 2026 | $1.2B |
| Dec 2025 | -$2.4B |
| Sep 2025 | $2.9B |
| Jun 2025 | -$74.0M |
| Mar 2025 | $3.2B |
| Dec 2024 | -$2.8B |
| Sep 2024 | $818.1M |
At each fiscal year end
Single quarter
Debt to equity
3.84x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity COR
| FY Sep 2025 | 5.08x |
| FY Sep 2024 | 6.79x |
| FY Sep 2023 | 9.17x |
| FY Sep 2022 | n/a |
| FY Sep 2021 | 29.93x |
| Jun 2026 | 3.84x |
| Mar 2026 | 3.65x |
| Dec 2025 | 4.15x |
| Sep 2025 | 5.08x |
| Jun 2025 | 4.16x |
| Mar 2025 | 7.76x |
| Dec 2024 | 35.96x |
| Sep 2024 | 6.79x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.41x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt COR
| FY Sep 2025 | 0.51x |
| FY Sep 2024 | 0.79x |
| FY Sep 2023 | 0.82x |
| FY Sep 2022 | 0.47x |
| FY Sep 2021 | 0.40x |
| Jun 2026 | 0.41x |
| Mar 2026 | 0.18x |
| Dec 2025 | 0.54x |
| Sep 2025 | 0.51x |
| Jun 2025 | 0.21x |
| Mar 2025 | 0.52x |
| Dec 2024 | -0.01x |
| Sep 2024 | 0.79x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+104.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity COR
| FY Sep 2025 | +144.3% |
| FY Sep 2024 | +258.4% |
| FY Sep 2023 | +1,124% |
| FY Sep 2022 | +28,806% |
| FY Sep 2021 | n/a |
| Jun 2026 | +104.3% |
| Mar 2026 | +115.6% |
| Dec 2025 | +152.3% |
| Sep 2025 | +144.3% |
| Jun 2025 | +130.6% |
| Mar 2025 | +161.6% |
| Dec 2024 | +245.3% |
| Sep 2024 | +258.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+3.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets COR
| FY Sep 2025 | +2.2% |
| FY Sep 2024 | +2.3% |
| FY Sep 2023 | +2.9% |
| FY Sep 2022 | +3.0% |
| FY Sep 2021 | +3.0% |
| Jun 2026 | +3.3% |
| Mar 2026 | +3.3% |
| Dec 2025 | +2.2% |
| Sep 2025 | +2.2% |
| Jun 2025 | +2.7% |
| Mar 2025 | +2.5% |
| Dec 2024 | +2.1% |
| Sep 2024 | +2.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+19.0%
operating income after a 26.8% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital COR
| FY Sep 2025 | +36.5% |
| FY Sep 2024 | +78.2% |
| FY Sep 2023 | +96.1% |
| FY Sep 2022 | +65.9% |
| FY Sep 2021 | +60.3% |
| Jun 2026 | +19.0% |
| Mar 2026 | +16.2% |
| Dec 2025 | +28.8% |
| Sep 2025 | +36.5% |
| Jun 2025 | +29.3% |
| Mar 2025 | +27.4% |
| Dec 2024 | +27.8% |
| Sep 2024 | +78.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+13.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed COR
| FY Sep 2025 | +16.6% |
| FY Sep 2024 | +16.4% |
| FY Sep 2023 | +17.5% |
| FY Sep 2022 | +16.3% |
| FY Sep 2021 | +17.8% |
| Jun 2026 | +13.6% |
| Mar 2026 | +12.9% |
| Dec 2025 | +15.9% |
| Sep 2025 | +16.6% |
| Jun 2025 | +16.2% |
| Mar 2025 | +15.9% |
| Dec 2024 | +14.5% |
| Sep 2024 | +16.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
24.50x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing COR
| FY Sep 2025 | 39.26x |
| FY Sep 2024 | 29.89x |
| FY Sep 2023 | 21.07x |
| FY Sep 2022 | 16.81x |
| FY Sep 2021 | 16.16x |
| Jun 2026 | 21.01x |
| Mar 2026 | 24.07x |
| Dec 2025 | 40.55x |
| Sep 2025 | 39.26x |
| Jun 2025 | 30.79x |
| Mar 2025 | 32.19x |
| Dec 2024 | 31.87x |
| Sep 2024 | 29.89x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$71.9B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value COR
| FY Sep 2025 | $63.9B |
| FY Sep 2024 | $45.6B |
| FY Sep 2023 | $38.6B |
| FY Sep 2022 | $30.4B |
| FY Sep 2021 | $29.0B |
| Jun 2026 | $64.0B |
| Mar 2026 | $71.3B |
| Dec 2025 | $71.7B |
| Sep 2025 | $63.9B |
| Jun 2025 | $64.1B |
| Mar 2025 | $59.8B |
| Dec 2024 | $48.4B |
| Sep 2024 | $45.6B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.4%
TTM free cash flow over market value at close 2026-10-26
FCF yield COR
| FY Sep 2025 | +5.3% |
| FY Sep 2024 | +6.8% |
| FY Sep 2023 | +9.5% |
| FY Sep 2022 | +7.9% |
| FY Sep 2021 | +9.0% |
| Jun 2026 | +7.4% |
| Mar 2026 | +2.5% |
| Dec 2025 | +5.5% |
| Sep 2025 | +5.3% |
| Jun 2025 | +2.0% |
| Mar 2025 | +6.6% |
| Dec 2024 | -1.5% |
| Sep 2024 | +6.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.64x
P/E over trailing EPS growth of 38%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing COR
| FY Sep 2025 | 6.88x |
| FY Sep 2024 | n/a |
| FY Sep 2023 | 3.46x |
| FY Sep 2022 | 1.88x |
| FY Sep 2021 | n/a |
| Jun 2026 | 0.55x |
| Mar 2026 | 0.47x |
| Dec 2025 | 2.23x |
| Sep 2025 | 6.88x |
| Jun 2025 | 5.46x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-09 | |
|---|---|---|---|---|
| Revenue | $321.3B | $294.0B | $262.2B | $238.6B |
| Gross profit | $11.5B | $9.9B | $9.0B | $8.3B |
| Operating income | $2.6B | $2.2B | $2.3B | $2.4B |
| Net income | $1.6B | $1.5B | $1.7B | $1.7B |
| EPS (diluted) | 7.96 | 7.53 | 8.53 | 8.04 |
| Operating cash flow | $3.9B | $3.5B | $3.9B | $2.7B |
| Cash | $4.4B | $3.1B | $2.6B | $3.4B |
| Long-term debt | $7.5B | $3.8B | $4.1B | $4.6B |
| Buybacks | $435.5M | $1.5B | $1.2B | $483.7M |
| Dividends paid | $437.1M | $416.2M | $398.8M | $391.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
COR Stock Sonar score 6/7 axes
Find similar shapesCompareCOR ranks highest on institutional and government (77th percentile) and growth (72nd), and lowest on financial health (32nd), among Wholesale & Retail peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
COR filings, in plain words
Are Cencora insiders buying or selling COR?
In the 180 days to 2026-10-28, Cencora insiders were net sellers, a net $2.4M: $2.3M of purchases and $4.7M of sales reported on Form 4, by 2 buyers and 3 sellers.
Have members of Congress traded COR?
Yes. In the year to 2026-10-28, 1 House member disclosed buying COR and 1 House member disclosed selling it; the latest on record is a sale by Jared Moskowitz dated 2026-05-06.
Are there planned insider sales of COR?
Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $16.4M of stock; the latest, by Lon Greenberg, was filed 2026-09-16.
Read the full summary
In the 180 days to 2026-10-28, Cencora insiders were net sellers of COR, a net $2.4M across purchases and sales reported on Form 4 by 2 buyers and 3 sellers. 50% of the 4 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying COR and 1 member disclosed selling it; the latest on record is a sale by Jared Moskowitz dated 2026-05-06. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $16.4M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
